Видео ютуба по тегу Jonathan Silverberg

Topical JAK Inhibitors | Jonathan Silverberg
Topical JAK Inhibitors | Jonathan Silverberg
Jonathan Silverberg | Dupilumab associated Facial Skin Changes
Jonathan Silverberg | Dupilumab associated Facial Skin Changes
Emerging Global and US Epidemiologic Trends in AD|Jonathan Silverberg, MD, MPH, PhD|Washington, D.C.
Emerging Global and US Epidemiologic Trends in AD|Jonathan Silverberg, MD, MPH, PhD|Washington, D.C.
Irritant contact dermatitis in AD patients | Jonathan Silverberg | Washington, D.C., USA
Irritant contact dermatitis in AD patients | Jonathan Silverberg | Washington, D.C., USA
Jonathan Silverberg Explores 'Atopic March', Age-Related Phenotypes, & Insurance Coverage in AD
Jonathan Silverberg Explores 'Atopic March', Age-Related Phenotypes, & Insurance Coverage in AD
Epidemiology ofAlopecia Areata&Atopic Comorbidities|Jonathan Silverberg, MD, MPH, PhD, Washington,DC
Epidemiology ofAlopecia Areata&Atopic Comorbidities|Jonathan Silverberg, MD, MPH, PhD, Washington,DC
High precipitation areas increase eczema by 30%!? (& learn other climate triggers) - Part 1
High precipitation areas increase eczema by 30%!? (& learn other climate triggers) - Part 1
The Quest for Itch Free, Clear Skin in Atopic Dermatitis New Practice Informing Evidence
The Quest for Itch Free, Clear Skin in Atopic Dermatitis New Practice Informing Evidence
Chapter 25: Combining Shared Decision-Making with Treat-to-Target Approaches in AD
Chapter 25: Combining Shared Decision-Making with Treat-to-Target Approaches in AD
Chapter 23: Flexible Dosing Regimens for Patients with AD
Chapter 23: Flexible Dosing Regimens for Patients with AD
When to suspect atopic dermatitis or alternate diagnoses
When to suspect atopic dermatitis or alternate diagnoses
Are these climates or US states increasing your risk for eczema?
Are these climates or US states increasing your risk for eczema?
Unpacking LEVEL UP Part 2: Overview of the Secondary Outcomes
Unpacking LEVEL UP Part 2: Overview of the Secondary Outcomes
Atopic Dermatitis Livestream 8/27/20 with Drs. Blaiss & Silverberg!
Atopic Dermatitis Livestream 8/27/20 with Drs. Blaiss & Silverberg!
The New Paradigm in Atopic Dermatitis Treatment: Line 6 Stop 7 Summary
The New Paradigm in Atopic Dermatitis Treatment: Line 6 Stop 7 Summary
From Heterogeneity Comes New Insights: Exploring the Role of T Cells & OX40 Signaling in Atopic D...
From Heterogeneity Comes New Insights: Exploring the Role of T Cells & OX40 Signaling in Atopic D...
Measuring Outcomes in Atopic Dermatitis
Measuring Outcomes in Atopic Dermatitis
Module 4 - Expert Analysis of Emerging Atopic Dermatitis Therapy Studies
Module 4 - Expert Analysis of Emerging Atopic Dermatitis Therapy Studies
Module 5 - Expert Analysis of Emerging Atopic Dermatitis Therapy Studies
Module 5 - Expert Analysis of Emerging Atopic Dermatitis Therapy Studies
Tralokinumab + TCS in AD: phase III results, J.I. Silverberg et al
Tralokinumab + TCS in AD: phase III results, J.I. Silverberg et al
Atopic Dermatitis: Comorbidities
Atopic Dermatitis: Comorbidities